International Journal of Endocrinology

Research Article

Metabolic Syndrome in People Living with Human Immunodeficiency Virus: An Assessment of the Prevalence and the Agreement between Diagnostic Criteria

Table 4

Kappa statistics and 95% confidence interval for the concordance between the JIS, IDF, and ATPIII 2005 metabolic syndrome criteria presented by gender and HIV-related subgroups ().


Group and subgroup	Criteria	IDF	JIS

Overall ()	IDF	—	0.96 (0.93–0.98)
Overall ()	ATPIII 2005	0.84 (0.80–0.89)	0.89 (0.86–0.93)
Men	IDF	—	0.79 (0.65–0.93)
Men	ATPIII 2005	0.62 (0.43–0.81)	0.88 (0.77–0.98)
Women	IDF	—	0.98 (0.96–1.00)
Women	ATPIII 2005	0.87 (0.83–0.92)	0.89 (0.85–0.93)
HIV duration—overall ()	IDF	—	0.96 (0.93–0.98)
HIV duration—overall ()	ATPIII 2005	0.84 (0.80–0.89)	0.89 (0.85–0.93)
yrs	IDF	—	0.96 (0.92–0.99)
yrs	ATPIII 2005	0.81 (0.73–0.89)	0.86 (0.79–0.92)
yrs	IDF	—	0.95 (0.92–0.99)
yrs	ATPIII 2005	0.86 (0.80–0.92)	0.91 (0.87–0.95)
CD4 count—overall ()	IDF	—	0.99 (0.97–1.00)
CD4 count—overall ()	ATPIII 2005	0.89 (0.84–0.94)	0.91 (0.86–0.95)
CD4 cells/mm³	IDF	—	0.99 (0.96–1.00)
CD4 cells/mm³	ATPIII 2005	0.86 (0.78–0.95)	0.88 (0.80–0.96)
CD4 cells/mm³	IDF	—	0.99 (0.96–1.00)
CD4 cells/mm³	ATPIII 2005	0.91 (0.85–0.98)	0.93 (0.87–0.98)
Antiretroviral therapy use—overall ()	IDF	—	0.95 (0.93–0.98)
Antiretroviral therapy use—overall ()	ATPIII 2005	0.85 (0.81–0.90)	0.90 (0.87–0.94)
No antiretroviral treatment	IDF	—	0.95 (0.86–1.00)
No antiretroviral treatment	ATPIII 2005	0.9 (0.77–1.00)	0.95 (0.86–1.00)
On antiretroviral treatment	IDF	—	0.95 (0.93–0.98)
On antiretroviral treatment	ATPIII 2005	0.85 (0.80–0.90)	0.90 (0.86–0.94)
1st-line antiretroviral therapy regimen	IDF	—	0.96 (0.93–0.99)
1st-line antiretroviral therapy regimen	ATPIII 2005	0.86 (0.80–0.92)	0.91 (0.86–0.95)
2nd-line antiretroviral therapy regimen	IDF	—	0.91 (0.81–1.00)
2nd-line antiretroviral therapy regimen	ATPIII 2005	0.85 (0.72–0.98)	0.94 (0.86–1.00)
Other antiretroviral therapy regimens	IDF	—	0.95 (0.90–1.00)
Other antiretroviral therapy regimens	ATPIII 2005	0.81 (0.71–0.91)	0.86 (0.77–0.95)

ATPIII: Adult Treatment Panel III; IDF: International Diabetes Federation; JIS: Joint Interim Statement; HIV: human immunodeficiency virus. Data were missing for some characteristics. For each grouping variable for which data were missing for some participants, the overall agreement between criteria in that subsample is provided.